Stroma biglycan expression can be a prognostic factor in prostate cancers
Stroma biglycan expression can be a prognostic factor in prostate cancers
复制标题
DOI：
10.1111/iju.15080
复制
发表时间：
2022-10
影响因子：
2.6
通讯作者：
Jun Furumido;N. Maishi;Aya Yanagawa-Matsuda;H. Kikuchi;R. Matsumoto;T. Osawa;T. Abe;Y. Matsuno;N. Shinohara;Y. Hida;K. Hida
中科院分区：
文献类型：
--
作者：
Jun Furumido;N. Maishi;Aya Yanagawa-Matsuda;H. Kikuchi;R. Matsumoto;T. Osawa;T. Abe;Y. Matsuno;N. Shinohara;Y. Hida;K. Hida
本研究分析了前列腺癌中双糖蛋白聚糖表达与临床病理参数之间的关系，以阐明双糖蛋白聚糖与预后和进展为去势抵抗性前列腺癌（CRPC）之间的潜在联系。
This study analyzes the relationship between biglycan expression in prostate cancer and clinicopathological parameters to clarify the potential link between biglycan and prognosis and progression to castration‐resistant prostate cancer (CRPC).